Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial | Semantic Scholar
Safety and Immunogenicity of H1/IC31H, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial
- K. ReitherL. Katsoulis G. Churchyard
- 2015
Medicine
The safety and immunogenicity of the novel H1/IC31 vaccine, a fusion protein of Ag85B-ESAT-6 (H1) formulated with the adjuvant IC31, was evaluated in HIV-infected adults in a phase II multi-centre, double-blind, placebo-controlled trial.